SCHEMBL7209282

SCHEMBL7209282

C[C@]12CCC(=O)C=C1CC[C@@H]1[C@H]2CC[C@@]2(C)[C@H]1CCC2(OC=O)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 6/20 0.65
NR3C1 P04150 4/20 0.65
PGR P06401 3/20 0.65
ALDH1A1 P00352 3/20 0.65
ADRA1A P35348 1/20 0.65
HTR2B P41595 1/20 0.65
AR P10275 2/20 0.63
LMNA P02545 6/20 0.63
SMN1; SMN2 Q16637 6/20 0.63
SERPINA6 P08185 5/20 0.63
BLM P54132 4/20 0.63
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
CYP2C19 P33261 3/20 0.63
ADORA3 P0DMS8 2/20 0.63
MAPT P10636 2/20 0.63
SLC6A3 Q01959 2/20 0.63
MAPK3 P27361 1/20 0.63
HIF1A Q16665 3/20 0.60
NPSR1 Q6W5P4 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11045530 0.91 LMNA (0.69) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL10598126 0.91 SHBG (0.67) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL10598120 0.91 SHBG (0.67) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL10602768 0.89 AR (0.66) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL10383760 0.88 AR (0.65) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL10385090 0.88 AR (0.65) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL10413142 0.88 AR (0.65) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL5697445 0.86 AR (0.60) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL8853536 0.84 LMNA (0.72) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL8937171 0.84 LMNA (0.72) SHBGNR3C1PGRALDH1A1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610675-B1 Identifying nontoxic therapeutically inactive metabolite of drug which elicits particular therapeutic response, converting inactive metabolite into activated structurally related drug species which cleaves in vivo to inactive metabolite Bodor, Nicholas S. 2003-08-26 US disclosed